Last reviewed · How we verify
Ticagrelor 90
At a glance
| Generic name | Ticagrelor 90 |
|---|---|
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Ticagrelor Monotherapy After Stenting (PHASE2)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (PHASE1)
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor 90 CI brief — competitive landscape report
- Ticagrelor 90 updates RSS · CI watch RSS
- Sheffield Teaching Hospitals NHS Foundation Trust portfolio CI